Tanzeel Ur. Rehman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tanzeel Ur. Rehman has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Alicja Gawalska
Faculty of Pharmacy, Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Cracow, Poland
1 shared publication- Islam Ullah Khan
Government College University
1 shared publication - Jahanzeb Malik
Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan
1 shared publication - Marek Bajda
Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland
1 shared publication Muhammad Ashraf
Department of Biochemistry and Biotechnology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
1 shared publication- Muhammad Mohsin
National Institute of Cardiovascular Diseases, Karachi, Pakistan
1 shared publication
Latest Publications
- 2 January 2022
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 20 (1) , 55-63
Echocardiography in a critical care unit: a contemporary review
Echocardiography is a rapid, noninvasive, and complete cardiac assessment tool for patients with hemodynamic instability. This review provides an overview of the evidence for current practices in c...
- 2 January 2022
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 20 (1) , 55-63
Echocardiography in a critical care unit: a contemporary review
Echocardiography is a rapid, noninvasive, and complete cardiac assessment tool for patients with hemodynamic instability. This review provides an overview of the evidence for current practices in c...
- 1 December 2017
- Published by Wiley in Archiv der Pharmazie
- Vol. 351 (1)
Novel pyridine‐2,4,6‐tricarbohydrazide thiourea compounds as small key organic molecules for the potential treatment of type‐2 diabetes mellitus: In vitro studies against yeast α‐ and β‐glucosidase and in silico molecular modeling
A range of novel pyridine‐2,4,6‐tricarbohydrazide thiourea compounds (4a–i) were synthesized in good to excellent yields (63–92%). The enzyme inhibitory potentials of these compounds were investigated against α‐ and β‐glucosidases because these enzymes play a crucial role in treating type‐2 diabetes mellitus (T2DM). As compared to the reference compound acarbose (IC50 38.22 ± 0.12 μM), compounds 4i (IC50 25.49 ± 0.67 μM), 4f (IC50 28.91 ± 0.43 μM), 4h (IC50 30.66 ± 0.52 μM), and 4e (IC50 35.01 ± 0.45 μM) delivered better inhibition against α‐glucosidase and were quite inactive/completely inactive against β‐glucosidase. The structure–activity relationship of these compounds was developed and elaborated with the help of molecular docking studies.
- 1 December 2017
- Published by Wiley in Archiv der Pharmazie
- Vol. 351 (1)
Novel pyridine‐2,4,6‐tricarbohydrazide thiourea compounds as small key organic molecules for the potential treatment of type‐2 diabetes mellitus: In vitro studies against yeast α‐ and β‐glucosidase and in silico molecular modeling
A range of novel pyridine‐2,4,6‐tricarbohydrazide thiourea compounds (4a–i) were synthesized in good to excellent yields (63–92%). The enzyme inhibitory potentials of these compounds were investigated against α‐ and β‐glucosidases because these enzymes play a crucial role in treating type‐2 diabetes mellitus (T2DM). As compared to the reference compound acarbose (IC50 38.22 ± 0.12 μM), compounds 4i (IC50 25.49 ± 0.67 μM), 4f (IC50 28.91 ± 0.43 μM), 4h (IC50 30.66 ± 0.52 μM), and 4e (IC50 35.01 ± 0.45 μM) delivered better inhibition against α‐glucosidase and were quite inactive/completely inactive against β‐glucosidase. The structure–activity relationship of these compounds was developed and elaborated with the help of molecular docking studies.